Clemmons 2017 — Tesamorelin T2D Safety Study

PLOS ONE

Clemmons DR, Miller S, Mamputu JC

Summary

No significant differences in HbA1c or diabetes control over 12 weeks

Study Details

Study Design

12-week randomized, placebo-controlled dose-finding

Indication

Glycemic safety in type 2 diabetes

Intervention

1 mg or 2 mg SC daily

Species

Human

Sample Size

53 subjects

Risk of Bias Assessment

Funded by Theratechnologies